# Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections

> **NCT07280598** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 30 (estimated)

## Conditions studied

- CF - Cystic Fibrosis
- Klebsiella Pneumoniae Infection
- E Coli Infections
- Staphylococcus Aureus Infection
- Achromobacter
- Stenotrophomonas Maltophilia Infection

## Interventions

- **DRUG:** Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics

## Key facts

- **NCT ID:** NCT07280598
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280598, "Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07280598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*